Oncology Study with Janssen
Chris Economos of physIQ and Bert Hartog of Janssen discuss how they are working with HagaHospital (The Hague, Netherlands) to deploy accelerateIQTM to detect physiological anomalies during and after anti-cancer treatment. Funded by Janssen Pharmaceuticals, the study is evaluating how clinicians can leverage this technology to proactively identify and manage adverse events that may result from chemotherapy and immunotherapy, with potential to establish safety-related digital biomarkers.
TOPICS: Real-World Data and Analytics
AUDIENCE: Clinical Trials